Bordetella pertussis binds human C1 esterase inhibitor during the virulent phase, to evade complement-mediated killing

Journal of Infectious Diseases

Volumn 195, Issue 4, 2007, Pages 585-588

  Marr, Nico ^a,b   Luu, Rachel A ^a,c   Fernandez, Rachel C ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c Coley Pharmaceutical Group ^*  (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; COMPLEMENT; COMPLEMENT COMPONENT C1S INHIBITOR; PROTEIN BRKA; UNCLASSIFIED DRUG;

ARTICLE; BACTERIAL VIRULENCE; BACTERICIDAL ACTIVITY; BACTERIUM CULTURE; BORDETELLA PERTUSSIS; COMPLEMENT SYSTEM; CONTROLLED STUDY; HUMAN; INFLAMMATION; MUTANT; NONHUMAN; PERTUSSIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; SERUM; WILD TYPE;

BORDETELLA PERTUSSIS; COMPLEMENT C1 INACTIVATOR PROTEINS; COMPLEMENT SYSTEM PROTEINS; HUMANS; MUTATION; PROTEIN BINDING; VIRULENCE;

EID: 33846798521     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/510913     Document Type: Article

References (15)

1. Caliezi C, Wuillemin WA, Zeerleder S, Redondo M, Eisele B, Hack CE. C1-esterase inhibitor: an anti-inflammatory agent and its potential use in the treatment of diseases other than hereditary angioedema. Pharmacol Rev 2000; 52:91-112.
2. Jiang H, Wagner E, Zhang H, Frank MM. Complement 1 inhibitor is a regulator of the alternative complement pathway. J Exp Med 2001; 194:1609-16.
3. Cai S, Dole VS, Bergmeier W, et al. A direct role for C1 inhibitor in regulation of leukocyte adhesion. J Immunol 2005; 174:6462-6.
4. Liu D, Cai S, Gu X, Scafidi J, Wu X, Davis AE III. C1 inhibitor prevents endotoxin shock via a direct interaction with lipopolysaccharide. J Immunol 2003; 171:2594-601.
5. Lathem WW, Bergsbaken T, Welch RA. Potentiation of C1 esterase inhibitor by StcE, a metalloprotease secreted by Escherichia coli O157: H7. J Exp Med 2004; 199:1077-87.
6. Fernandez RC, Weiss AA. Serum resistance in bvg-regulated mutants of Bordetella pertussis. FEMS Microbiol Lett 1998; 163:57-63.
7. Musser JM, Hewlett EL, Peppler MS, Selander RK. Genetic diversity and relationships in populations of Bordetella spp. J Bacteriol 1986; 166:230-7.
8. Parkhill J, Sebaihia M, Preston A, et al. Comparative analysis of the genome sequences of Bordetella pertussis, Bordetella parapertussis and Bordetella bronchiseptica. Nat Genet 2003; 35:32-40.
9. Walker KE, Weiss AA. Characterization of the dermonecrotic toxin in members of the genus Bordetella. Infect Immun 1994; 62:3817-28.
10. Oliver DC, Fernandez RC. Antibodies to BrkA augment killing of Bordetella pertussis. Vaccine 2001; 20:235-41.
11. Fernandez RC, Weiss AA. Cloning and sequencing of a Bordetella pertussis serum resistance locus. Infect Immun 1994; 62:4727-38.
12. Peppler MS, Kuny S, Nevesinjac A, et al. Strain variation among Bordetella pertussis isolates from Quebec and Alberta provinces of Canada from 1985 to 1994. J Clin Microbiol 2003; 41:3344-7.
13. Monack DM, Arico B, Rappuoli R, Falkow S. Phase variants of Bordetella bronchiseptica arise by spontaneous deletions in the vir locus. Mol Microbiol 1989; 3:1719-28.
14. Elder KD, Harvill ET. Strain-dependent role of BrkA during Bordetella pertussis infection of the murine respiratory tract. Infect Immun 2004; 72:5919-24.
15. Berggard K, Johnsson E, Mooi FR, Lindahl G. Bordetella pertussis binds the human complement regulator C4BP: role of filamentous hemagglutinin. Infect Immun 1997; 65:3638-43.